China NMPA Product Recall - BiPAP autoSV Advanced System One ventilator, BiPAP autoSV ventilator

Philips (China) Investment Co., Ltd. issued a voluntary recall, reported to the National Medical Products Administration (NMPA) on June 1, 2015, for its BiPAP autoSV Advanced System One and BiPAP autoSV ventilators. This action stemmed from an industry safety bulletin, specifically from ResMed, highlighting an elevated cardiovascular mortality risk associated with similar servo ventilation (ASV) devices. The key issue identified is a statistically significant 2.5% absolute increase in annual cardiovascular mortality risk, which rose to 10.0% for patients with symptomatic chronic heart failure (NYHA class 2-4) and reduced left ventricular ejection fraction (LVEF "\u2264" 45%). No adverse risks were found in other patient groups. Philips is actively assessing the implications for its own devices under the NMPA's framework. Required actions include advising clinicians to avoid initiating ASV treatment for new high-risk patients. For existing patients, an objective LVEF assessment is mandated, with those in high-risk categories requiring evaluation to consider discontinuing ASV. Philips will disseminate customer notification letters and press releases to distributors, who are responsible for informing prescribing physicians and affected patients.